Lakefront Biotherapeutics is a Belgian biotechnology company developing medicines for serious immune and inflammatory diseases. LKFT reports earnings on Wed, Nov 11, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 23 | RBC Capital | Upgrade | Buy | |
| Aug 11 | Morgan Stanley | Maintained | Hold | |
| Aug 11 | RBC Capital | Maintained | Hold |
Seasonality
How LKFT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2012.
Whale Options Flow
90DNo whale options trades in LKFT in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether LKFT is in one of them and how their past LKFT trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered LKFT in an article yet. Here's the latest on the wider market.
About Lakefront Biotherapeutics NV
Lakefront Biotherapeutics is a biotechnology company based in Mechelen, Belgium, that develops medicines for patients with serious diseases. Its main focus is immunology, where its lead candidate is an oral medicine being studied in lupus and dermatomyositis, two autoimmune conditions. The company has also decided to wind down its cell therapy work in cancer and is seeking new business development deals to advance its remaining drug candidates.
- Headquarters
- 2800 Mechelen
- Founded
- 1999
- Website
- glpg.com ↗